Cirrhotic Patients with Gastroesophageal Variceal Bleeding Octreotide Terlipressin Acute Kidney Injury Gastroesophageal Variceal Bleeding
Conditions
Interventions
1) Once enrolled, patients were randomly allocated to the following two groups using sealed opaque envelopes numbered: terlipressin and octreotide groups.
2) Randomization was conducted using computer
Experimental Drug,Active Comparator Drug
Terlipressin,Octreotide
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age between 20 and 80 years. 2) Liver cirrhosis with evidence of portal hypertension. 3) Arrival at the hospital with upper gastrointestinal bleeding. 4) Patients agreeing to participate in this trial with informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who were diagnosed with non-variceal bleeding on endoscopy. 2) Patients presenting with acute kidney injury (increase in baseline serum creatinine level of >=0.3 mg/dL or a 50% rise from baseline levels). 3) Patients having cardiovascular disease, peripheral vascular disease, or advanced pulmonary disease. 4) Hypersensitivity to terlipressin or octreotide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of acute kidney injury (AKI) 48 hrs. using KDIGO criteria increase in serum creatinine | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of renal function 5 days Creatinine level,The 5-day rebleeding rates 5 days Bleeding status,The mortality in first five days 5 days Mortality status,The length of hospital stays discharge time length of hospital stays,The adverse events end of study adverse events after treatment | — |
Countries
Thailand
Contacts
Public ContactManatchaya Pongamnuaykrit
Faculty of Medicine, Chiang Mai University
Outcome results
None listed